Global Glucagon-like Peptide 1 (GLP-1) Analogues Market - 2025-2033

Glucagon-like Peptide 1 (GLP-1) Analogues Market Glucagon-like Peptide 1 (GLP-1) Analogues Market reached US$ 62.81 Billion in 2024 and is expected to reach US$ 299.08 Billion by 2033, growing at a CAGR of 17.6 % during the forecast period 2025-2033.

Glucagon-like peptide-1 (GLP-1) analogues, commonly known as GLP-1 receptor agonists or incretin mimetics, are a category of medications that replicate the actions of the naturally occurring hormone GLP-1. This hormone is secreted by the intestines after food consumption and is essential for glucose regulation. It enhances insulin secretion, inhibits glucagon release, and promotes feelings of fullness. These medications are mainly utilised to treat type 2 diabetes and obesity, as they effectively lower blood sugar levels and assist in weight loss by reducing appetite and caloric intake.

Key drivers fueling this momentum include a strong product pipeline with innovative molecules and combination therapies, and increased healthcare spending in emerging economies. Opportunities in the GLP-1 analogues market are abundant, particularly in expanding therapeutic applications, strategic collaborations, mergers, and acquisitions are reshaping the competitive landscape, while the increasing acceptance of GLP-1 therapies for chronic weight management is opening new revenue streams.

Major trends include the rapid growth of the obesity drug segment, the introduction of innovative products like CagriSema and oral GLP-1 agonists, and the continued dominance of North America and Europe, which together account for over 70% of the market share.

Glucagon-like Peptide 1 (GLP-1) Analogues Market Dynamics: Drivers

Increasing prevalence of obesity and  type 2 diabetes

Obesity is a chronic and multifaceted disease characterised by an accumulation of excessive fat that can negatively impact health. It is associated with a heightened risk of developing type 2 diabetes and heart disease, and it can also affect bone health and reproductive functions. Additionally, obesity increases the likelihood of certain cancers. It can significantly influence the quality of life, affecting aspects such as sleep and mobility.

The rising rates of type 2 diabetes and obesity present a major public health challenge. Both conditions are linked to serious health complications, such as cardiovascular diseases, hypertension, and metabolic syndrome. As lifestyle changes, including poor dietary habits and decreased physical activity, lead to higher rates of these conditions, the demand for effective treatment options has glucagon-like peptide 1 (GLP-1) analogues.

According to the World Health Organisation (WHO), obesity has nearly tripled, emphasising the urgent need for effective management strategies such as glucagon-like peptide 1 (GLP-1) analogues. In 2022, 1 in 8 individuals globally were living with obesity. The prevalence of adult obesity has more than doubled, while adolescent obesity has seen a fourfold increase.

Approximately 2.5 billion adults aged 18 and older were classified as overweight, with 890 million of them living with obesity. Among adults over 18, 43% were overweight and 16% were considered obese. Additionally, 37 million children under the age of 5 were overweight, and over 390 million children and adolescents aged 5 to 19 were overweight in 2022, including 160 million who were living with obesity.

For instance, in August 2024, Eli Lilly and Company announced positive topline results from the SURMOUNT-1 trial, a three-year study evaluating the effectiveness and safety of tirzepatide (marketed as Zepbound and Mounjaro) administered once weekly for long-term weight management and delaying the progression to diabetes in adults with pre-diabetes and obesity or overweight. All these factors demand the global glucagon-like peptide 1 (GLP-1) analogues market.

Glucagon-like Peptide 1 (GLP-1) Analogues Market Dynamics: Restraints

High cost of medications

The high cost of glucagon-like peptide 1 (GLP-1) analogues serves as a significant constraint in the global market for these medications. With monthly treatment expenses reaching about US$ 1,000, many patients find these drugs prohibitively expensive, particularly those without comprehensive insurance coverage. This financial strain results in limited access for a large segment of the population, as numerous insurance providers are reluctant to cover these costly medications.

According to the Yale School of Medicine data in April 2024, research has revealed that biosimilar manufacturers could sell insulin at prices 97% lower than current U.S. market rates, while GLP-1 agonist drugs like semaglutide (Ozempic and Wegovy), which cost Americans up to US$ 1,000 per month, could potentially be produced for less than US$ 1.

The estimated cost-based prices for insulin ranged from US$ 61 to US$ 111 annually, in stark contrast to the current market prices, which vary between US$ 98 and US$ 1,300 across 13 countries with different income levels. Similarly, the estimated monthly prices for GLP-1 agonists were calculated to be between US$ 0.75 and US$ 72.49, whereas the actual monthly price in the U.S. is approximately US$ 968.52. Thus, the above factors could be limiting the global glucagon-like peptide 1 (GLP-1) analogues market's potential growth.

Glucagon-like Peptide 1 (GLP-1) Analogues Market - Segment Analysis

The global glucagon-like peptide 1 (GLP-1) analogues market is segmented based on product, type, route of administration, application, distribution channel, and region.

Product:

Ozempic product type segment is expected to hold 27.5% of the global glucagon-like peptide 1 (GLP-1) market in 2024

Glucagon-like peptide-1 (GLP-1) is a physiological hormone that plays a crucial role in glucose metabolism. It exerts its effects through the GLP-1 receptor (GLP-1R), which is found in various cell types, including pancreatic beta cells. Ozempic, a GLP-1 receptor agonist, selectively binds to and activates the GLP-1 receptor, mimicking the action of native GLP-1.

Ozempic is a modified form of GLP-1 with approximately 94% sequence homology to human GLP-1. Structural modifications enhance its pharmacological properties. These modifications result in a longer half-life, allowing for once-weekly dosing rather than daily administration. The alterations make Ozempic resistant to enzymatic breakdown by dipeptidyl peptidase IV (DPP-IV), which normally degrades native GLP-1 rapidly.

For instance, in January 2025, the U.S. Food and Drug Administration (FDA) has approved Ozempic (semaglutide) as the first and only GLP-1 receptor agonist (GLP-1 RA) specifically indicated to reduce the risk of worsening kidney disease, kidney failure, and cardiovascular death in adults with type 2 diabetes and chronic kidney disease (CKD).

This expanded approval is based on results from the pivotal FLOW phase 3b clinical trial, which demonstrated that once-weekly semaglutide led to a statistically significant 24% reduction in the risk of kidney disease progression, kidney failure, and cardiovascular death compared to placebo, when added to standard care.

Glucagon-like Peptide 1 (GLP-1) Analogues Market Geographical Analysis

North America is expected to hold 42.5% of the global glucagon-like peptide 1 (GLP-1) market in 2024

The rising rates of obesity and type 2 diabetes in North America are driving the demand for effective treatment options. As more individuals are diagnosed with these conditions, the need for glucagon-like peptide 1 (GLP-1) analogue therapies continues to grow.

North America benefits from a well-established healthcare system that supports the adoption of advanced therapies. This infrastructure facilitates patient access to glucagon-like peptide 1 (GLP-1) analogues, ensuring that healthcare providers can effectively prescribe and monitor these treatments. The presence of favourable reimbursement frameworks in the U.S. encourages healthcare providers to prescribe glucagon-like peptide 1 (GLP-1) analogues.

For instance, in December 2024, the U.S. Food and Drug Administration (FDA) approved the first generic version of Victoza (liraglutide injection) at the 18 mg/3 mL strength. Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist, a type of injectable medication used to help lower blood sugar levels in people with type 2 diabetes.

This generic is approved for use in both adults and children aged 10 years and older as an add-on to diet and exercise to improve glycemic control.  Thus, the above factors are consolidating the region's position as a dominant force in the global glucagon-like peptide 1 (GLP-1) analogues market.

Asia-Pacific is expected to hold 19.8% of the global glucagon-like peptide 1 (GLP-1) market in 2024

The Asia-Pacific region is seeing a notable increase in cases of type 2 diabetes and obesity, primarily due to lifestyle changes, urbanisation, and unhealthy dietary habits. This surge in diagnoses is fueling the demand for effective treatment options like glucagon-like peptide 1 (GLP-1) analogues.

The ageing demographic in Asia-Pacific is projected to grow significantly, with individuals aged 60 and above expected to nearly double by 2050. Older adults are more susceptible to developing type 2 diabetes, which will drive the demand for GLP-1 therapies designed to manage their health effectively.

For instance, in January 2024, Glenmark Pharmaceuticals Ltd. made a significant entry into the Indian pharmaceutical market by launching Lirafit, a biosimilar of the widely used anti-diabetic drug liraglutide. This marks the first time a biosimilar of liraglutide has been introduced in India, following approval from the Drug Controller General of India (DCGI). Thus, the above factors are consolidating the region's position as the fastest-growing force in the global glucagon-like peptide 1 (GLP-1) analogues market.

Glucagon-like Peptide 1 (GLP-1) Analogues Market Major Players

The global players in the glucagon-like peptide 1 (GLP-1) analogues market include Eli Lilly and Company, Novo Nordisk A/S., Sanofi, AstraZeneca, Boehringer Ingelheim, Inc., Glenmark Pharmaceuticals Ltd., Hanmi Pharm. Co.., Ltd, Amgen Inc., Gmax Biopharm., and Sciwind Biosciences Co., Ltd., among others.

Glucagon-like Peptide 1 (GLP-1) Analogues Market Emerging Players

The emerging players in the glucagon-like peptide 1 (GLP-1) analogues market include Gmax Biopharm., Sciwind Biosciences Co., Ltd., Teva Pharmaceuticals, Inc., Hikma Pharmaceuticals PLC (Hikma), Viking Therapeutics, Terns Pharmaceuticals, Inc., Altimmune, AVVA Pharmaceuticals Ltd, LEXICARE PHARMA PVT. LTD., and Natco Pharma Limited, among others.

Key Developments

In April 2025, Meitheal Pharmaceuticals, Inc., announced that it received approval from the U.S. Food and Drug Administration (FDA) for its liraglutide injection (18 mg/3 mL). Following this approval, Meitheal has launched this product in the U.S. market.

In February 2025, Biocon Limited, a leading Indian biopharmaceutical company, announced the launch of its GLP-1 peptide drug, Liraglutide, in the United Kingdom. This marks a significant milestone for Biocon as it expands its presence in the global diabetes and obesity treatment markets.

In January 2025, Metsera, a New York-based obesity healthcare company, announced positive topline results from its Phase IIa clinical trial for MET-097i, a glucagon-like peptide-1 receptor agonist (GLP-1RA). This investigational drug is designed to combat obesity and is particularly noteworthy for its potential once-monthly dosing, which could offer a significant advantage over existing treatments that typically require more frequent administration.

In September 2024, Terns Pharmaceuticals announced positive results from its Phase 1 clinical trial for TERN-601, a once-daily oral GLP-1 receptor agonist aimed at treating obesity. This trial was designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of TERN-601 in healthy adults with obesity or overweight conditions.

In September 2024, Kourtney Kardashian launched a new weight loss product called Lemme GLP-1 Daily capsules, expanding her wellness brand, Lemme. This product is designed to promote health and nutrition, aligning with Kourtney's ongoing commitment to wellness through her lifestyle platform, Poosh.

In August 2024, Metsera, a newly launched clinical-stage biopharmaceutical company, emerged with a significant US$ 290 million in funding to develop innovative treatments for obesity and metabolic diseases, particularly focusing on GLP-1 receptor agonists.

In June 2024, Teva Pharmaceuticals announced the launch of the first generic version of a GLP-1 receptor agonist in the United States, specifically liraglutide 1.8 mg. This marks a significant milestone in the diabetes treatment landscape as it introduces a more affordable option for patients managing type 2 diabetes.

The global glucagon-like peptide 1 (GLP-1) analogues market report would provide approximately 78 tables, 76 figures, and 183 pages.